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Abstract
Evidence supporting a role for estrogen in male reproductive tract development and function has
been collected from rodents and humans.  These studies fall into three categories: i) localization of
aromatase and the target protein for estrogen (ER-alpha and ER-beta) in tissues of the reproductive
tract; ii) analysis of testicular phenotypes in transgenic mice deficient in aromatase, ER-alpha and/
or ER-beta gene; and, iii) investigation of the effects of environmental chemicals on male
reproduction.  Estrogen is thought to have a regulatory role in the testis because estrogen
biosynthesis occurs in testicular cells and the absence of ERs caused adverse effects on
spermatogenesis and steroidogenesis.  Moreover, several chemicals that are present in the
environment, designated xenoestrogens because they have the ability to bind and activate ERs, are
known to affect testicular gene expression.  However, studies of estrogen action are confounded
by a number of factors, including the inability to dissociate estrogen-induced activity in the
hypothalamus and pituitary from action occurring directly in the testis and expression of more than
one ER subtype in estrogen-sensitive tissues.  Use of tissue-specific knockout animals and
administration of antiestrogens and/or aromatase inhibitors in vivo may generate additional data to
advance our understanding of estrogen and estrogen receptor biology in the developing and mature
testis.
Introduction
The testis consists of two compartments: seminiferous
tubules and intertubular tissue, which forms the intersti-
tium. Seminiferous tubules are lined by layers of germ
cells in various stages of development (spermatogonia,
spermatocytes, spermatids, spermatozoa) and supporting
Sertoli cells. The interstitium consists of loose connective
tissue, blood and lymphatic vessels, and various cell types,
including Leydig cells, fibroblasts, macrophages and leu-
kocytes. Leydig cells are the predominant source of the
male sex steroid hormone testosterone. However, recent
observations challenge the dogma that the male pheno-
type is maintained solely by testosterone binding to its
protein target, i.e., the androgen receptor. Growing public
concerns that exposures to environmental chemicals with
estrogenic activity may impact human reproductive
health have focused attention on the role of estrogen in
male reproductive health [1]. The aromatization of C19
androgens, i.e., testosterone and androstenedione, is a key
step in estrogen (E2) biosynthesis and is catalyzed by the
aromatase enzyme, which is a product of the CYP19 gene
[2]. The serum levels of E2 measure about 40 pg/mL in
male rats [3], and ranges between 20 and 40 pg/mL in
men [4]. Evidence from several studies indicates that aro-
matase, ERα and ERβ are encoded by separate genes but
are co-expressed with androgen receptors in the male
reproductive tract [2,3]. In consonance with localization
studies, mice which have targeted deletion of the aro-
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matase gene, ERα and/or ERβ showed altered testicular
morphology and derangements of spermatogenesis [5-7],
and exposures of laboratory species and wildlife to estro-
genic chemicals were found to cause abnormalities of the
reproductive tract [8].
Although the present review is focused on direct estrogen
action in the testis, estrogen regulation may occur indi-
rectly by changes caused in the hypothalamus and pitui-
tary. Gonadal steroids act on the hypothalamus to affect
GnRH pulses, and at the pituitary level to regulate gona-
dotropin (FSH and LH) secretion. FSH and LH are the pri-
mary tropic hormones that regulate testicular function.
Indeed, FSH receptors are expressed only in Sertoli cells,
and Leydig cells are the only binding sites for LH in the
testis. In contrast, ERs have a more diversified pattern of
expression. There is conclusive evidence showing that ERα
and ERβ are present in several hypothalamic nuclei and in
pituitary gonadotropes, indicating that estrogen regulates
the hypothalamus-pituitary axis [9,10]. For example, E2
treatment of a mouse gonadotroph cell line (LβT2)
increased LH secretion and, following co-incubation with
GnRH, increased LHβ mRNA levels [11]. Furthermore, the
presence of estrogen-response-elements (EREs) on the
promoter region of the β-subunit of the LH gene has been
reported, implying that estrogen regulation of LH secre-
tion occurs directly at the level of the LHβ gene [12,13].
There is also evidence that ERα can be transcriptionally
activated in gonadotrope cells in an estrogen-independent
manner, through the GnRH receptor and signaling via
protein kinase C (PKC) and mitogen-activated protein
kinase (MAPK) pathways [14]. Together, these observa-
tions demonstrate that estrogen regulation of testicular
function is also mediated indirectly by changes occurring
in the hypothalamus and pituitary.
Estrogen Receptors
ERs are members of the steroid/thyroid hormone super
family of nuclear receptors, which share a common struc-
tural architecture, and consist of three independent but
interacting functional domains: the N-terminal or A/B
domains, the C or DNA-binding domain, and the D/E/F
or ligand-binding domain (Fig 1). Binding of a ligand to
the ER causes a series of downstream events, including
receptor dimerization, receptor-DNA interactions medi-
ated by EREs present in the promoter region of target
genes, recruitment of and interaction with transcription
factors, and the formation of a preinitiation complex. Lig-
and-receptor interactions ultimately cause changes in tar-
get gene expression [15]. The N-terminal domain of
nuclear receptors encodes an activation function called
AF-1, which mediates protein-protein interactions to
induce transcriptional activity. It is thought that this
domain is highly active in ERα-mediated stimulation of
reporter gene expression from a variety of ERE-constructs
but its activity in the ERβ is limited [16]. On the other
hand, the C-terminal or ligand-binding domain contains
the AF-2 interacting surface that mediates ligand binding
and receptor dimerization to stimulate transcriptional
activity [17]. Thus, AF-1 and AF-2 are both involved in
mediating the transcriptional activation functions of ERs.
Although there is a high degree of homology in the DNA-
binding domains of ERα and ERβ (about 95%), only a
partial homology exists in the ligand-binding domain
(~60%) [18]. Differences in ligand binding, in association
with other factors, have the effect of altering the pattern of
ER-mediated transcriptional activity. For example, some
agonists bind both ER subtypes with the same affinity
while others preferentially bind to ERα or ERβ [19-21].
There is general agreement that ERs function as dimers,
and co-expression of ERα and ERβ in the same cell causes
the formation of homodimers (ERα/ERα and ERβ/ERβ)
or heterodimers (ERα/ERβ), which affect ligand-specifi-
city. The interactions between ERs and EREs are compli-
cated by other factors, including the ability of ERβ to
modulate ERα transcriptional activity and recruitment of
several protein co-activators and repressors by both ER
subtypes. Therefore, the relative amounts of ERα and ERβ
in a given tissue are key determinants of cellular responses
to estrogen and other ER agonists and antagonists [22].
Moreover, ER and other steroid receptors have the ability
to mediate biological effects through non-transcriptional
mechanisms mediated by protein-protein interactions
occurring between ERs and growth factors e.g., IGF-1 and
EGF [23,24]. Furthermore, there is growing evidence for
the presence of a small pool of ERs localized to the plasma
membrane. For example, BSA-conjugated E2, which is
unable to gain entry into the cytosol and acts at the
plasma membrane, decreased testicular androgen produc-
tion  in vitro [25]. Membrane ER is thought to signal
mainly by coupling to GTP-activating proteins and
through pathways involving second messengers (e.g., cal-
cium) and kinase cascades [26]. The integration of several
pathways implies that estrogen action in any particular tis-
sue and organ is the result of activities mediated by
genomic and non-genomic pathways although the physi-
ological significance of specific pathways in the testis
remains to be elucidated [27].
I. Localization of aromatase and ERs
Data describing aromatase activity and ER expression in
reproductive tissues were collected using a combination
of techniques: binding assays, immunohistochemistry, in
situ hybridization, reverse transcriptase-polymerase chain
reaction (RT-PCR), and RNase protection assays. In spite
of the large body of information derived from these stud-
ies, localization studies have shortcomings that limit data
interpretation regarding ER expression in specific tissues.
For example, binding assays do not distinguish betweenReproductive Biology and Endocrinology 2005, 3:51 http://www.rbej.com/content/3/1/51
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ERα and ERβ while in situ hybridization studies measure
mRNA levels but do not determine whether mRNA is
translated to protein. Similarly, immunocytochemistry
lacked specificity for either ER subtype. However, the
availability of antibodies directed against ERα, and much
later for ERβ, allowing for discrimination between ER sub-
types in subsequent studies has generated substantial
information on ER biology.
During fetal development in the rodent, aromatase is
expressed in Sertoli cells and Leydig cells but not in sper-
matogonia. On the other hand, aromatase has been local-
ized to virtually all cell types in the adult testis, including
Leydig cells, Sertoli cells, spermatocytes, spermatids and
spermatozoa [6,28,29]. Cellular expression of aromatase
is age-dependent in the postnatal rat, occurring predomi-
nantly in Sertoli cells and germ cells of the prepubertal tes-
tis (up to 21 days of age) and in Leydig cells after this
period [30]. Taken together, the bulk of data collected
from the rodent testis point to a general pattern of ERα
expression in Leydig cells and peritubular myoid cells and
ERβ in germ cells [10,31-33]. However, ERβ was localized
to adult Leydig cells in the mouse [34], and both ERα and
ERβ were found to be present in rat fetal and adult Leydig
cells [35]. Similarly, ERα and ERβ were immunolocalized
to Leydig cells in pubertal rats although treatment with
the pure antiestrogen ICI 182,780 abolished ERα, but not
ERβ, protein [36]. Consistent with ER expression in
diverse cell types in the testis, it is not surprising that
administration of ER agonists and antagonists or targeted
deletion of the aromatase gene and ERs caused derange-
ments in germ cell development and testicular
steroidogenesis.
Unlike in rodents, aromatase activity and estrogen biosyn-
thesis occur mostly in adipose tissue in men, and the testis
synthesizes only 10–25% of E2 in circulation [37]. Early
studies showed that prenatal exposures to the synthetic
estrogen diethylstilbestrol (DES) caused male reproduc-
tive tract abnormalities in mice [38] and men [39]. In
agreement with these observations, ERα and ERβ were
localized to the human testis, and the presence of two var-
iants of ERβ, designated ERβ1 and ERβ2, has been clearly
demonstrated [40]. Although ERβ mRNA levels were 3-
fold greater than ERα, both were expressed in the testis
beginning from 16 weeks of gestation [41]. ERβ1 was
more widely expressed in Sertoli cells, germ cells and Ley-
dig cells while ERβ2 mRNA and protein were restricted to
spermatogonia [42]. In the adult testis, both ERα and ERβ
are expressed in spermatocytes, elongating spermatids,
Sertoli cells and Leydig cells [43,44]. Other studies have
demonstrated the presence of ERα in spermatids and
mature spermatozoa [45], ERβ in all germ cells [46,47],
and the absence of ERα in Leydig cells [48]. ERβ1 appears
An illustration of the structure of the estrogen receptor Figure 1
An illustration of the structure of the estrogen receptor. The NH2 terminal consists of the A/B domains, the C domain forms 
the DNA-binding domain (DBD) while domains D/E/F constitute the ligand-binding domain (LBD). The AF-1 and AF-2 activa-
tion units are part of the DNA-binding and ligand-binding domains, respectively. The two ER subtypes, ERα and ERβ, are 
almost identical in the DNA-binding domain (~95% homology) but differ in the ligand-binding domain (about 60% homology). 
Differences in the ligand-binding domain are responsible in part for ligand-specificity, and the ratio of ERα and ERβ is a critical 
determinant of cellular response to endogenous estrogen and other ER agonists and antagonists.Reproductive Biology and Endocrinology 2005, 3:51 http://www.rbej.com/content/3/1/51
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to be expressed at high levels in pachytene spermatocytes
and round spermatids but much less so in Sertoli cells and
spermatogonia whereas expression of ERβ2 is high in Ser-
toli cells and spermatogonia and is reduced in spermato-
cytes [49,50]. Although the physiological significance of
ERβ isoforms in the human testis remains to be clarified,
it has been suggested that ERβ2 forms heterodimers with
ERα thereby attenuating its transcriptional activity; how-
ever, it lacks the ability to bind endogenous E2 or recruit
cofactors via the AF-2 domain [51].
II. Transgenic mouse studies
Reports of testicular anomalies in men with naturally
occurring mutations in the aromatase gene and in individ-
uals lacking a functional ERα, including undescended tes-
tis, decreased sperm production, and altered endocrine
profiles, reinforced the view that estrogen action is a
requirement for normal testicular function [52-55]. Thus,
development of knockout or transgenic mice with disrup-
tion of molecules related to reproduction and hormone
action, e.g., mice with targeted deletion of the aromatase
gene (ARKO), ERα (αERKO), ERβ (βERKO) and both ER
subtypes (αβERKO), has contributed immensely to our
understanding of reproductive endocrinology [56]. A
major difference between these lines of mutant mice is
that ARKO mice adequately express ERα and ERβ protein
and do not make endogenous E2 whereas ER knockout
mice are able to synthesize E2 but lack either ERα and/or
ERβ protein. Therefore, a major caveat in these studies is
the inadvertent removal of estrogen priming of extrago-
nadal tissues during development. In this regard, there is
a possibility that absence of endogenous E2 and/or ER-
mediated activity during tissue differentiation in the
hypothalamus and pituitary jeopardizes developmental
maturation of regulatory pathways in the HPT axis.
The spectrum of testicular anomalies exhibited by trans-
genic mice deficient in E2 biosynthesis and ER protein is
summarized in Table 1. ARKO mice have enlarged sex
accessory organ weights presumably as a result of elevated
serum testosterone levels and enhanced androgen action,
and show disturbances of spermatogenesis, which is asso-
ciated with increased apoptosis of developing germ cells
[6,7]. However, the results of fertility assessment in ARKO
mice have been rather inconsistent, sexual function being
impaired in one line of mice and not in the other; these
differences are thought to be due to the amounts of resid-
ual aromatase gene products in mutant mice [7,57]. In
contrast to the lack of E2, overexpression of the aromatase
gene and enhanced E2 production in mice induced cryp-
torchidism or undescended testis, spermatogenic arrest,
Leydig cell hyperplasia, and decreased serum FSH and tes-
tosterone levels. Disruption of spermatogenesis was asso-
ciated with decreased FSH levels while increased
exposures to E2 induce Leydig cell hyperplasia [58]. Pro-
gressive degeneration of testicular tissue, dilation of the
seminiferous tubules, and sexual behavioral problems are
typical findings in αERKO mice [5]. Disruption of sper-
matogenesis has been attributed to fluid retention, which
causes pressure atrophy of the seminiferous epithelium
[59].
The obvious differences in the phenotypes of ARKO and
αERKO mice, as were determined in early studies, implied
that ERα is not the sole mediator of estrogen action and
that another ER protein may be present in testicular cells.
These speculations were confirmed by cloning of ERβ in
the rat prostate and ovary [60]. Subsequently, the bulk of
experimental evidence shows that ERβ regulates germ cell
development. For example, ERα inactivation had no effect
on the number of Sertoli cells and spermatogonia whereas
ERβ inactivation increased the number of spermatogonia
by more than 50% in neonatal mice [61]. However, it is
surprising that in spite of the evidence for ERβ regulation
of mitosis in spermatogonia, which serve as stem cells for
the process of spermatogenesis, disturbances of sperm
production were not evident in βERKO mice. On the other
hand, the presence of ERα in Sertoli cells has not been
demonstrated. Paradoxically, spermatogenic arrest occurs
in αERKO mice, which have ERβ protein. These observa-
tions suggest that testicular cells regulate Sertoli cell sup-
port of germ cell development through unidentified ERα-
mediated mechanisms. This line of thinking is supported
by data from experiments in which germ cells were
transplanted from donor males homozygous for the
mutation ERα-/-  to testes of wild-type ERα+/+ recipient
mice depleted of germ cells. When mated to wild-type
females, the recipients sired offspring heterozygous for the
Table 1: Testicular function in mice deficient in estrogen biosynthesis or estrogen receptor protein
Spermatogenesis Steroidogenesis Fertility References
ARKOa Affected Affected Affected 6,7
αERKOb Affected Affected Affected 5
βERKOc Normal Normal Normal 66
αβERKOd Affected Affected Affected 64Reproductive Biology and Endocrinology 2005, 3:51 http://www.rbej.com/content/3/1/51
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mutation ERα+/- but retained the coat-color marker of the
ERα-/- donor mice. This finding confirmed that somatic
cells in the testis, but not germ cells, have a requirement
for ERα in order to support the process of spermatogene-
sis [62,63]. In contrast to the αERKO, βERKO males retain
full fertility but tend to show increased incidence of pros-
tate hyperplasia with advancing age [64]. Perhaps not
unexpectedly, male αβERKO mice are infertile, which is
likely due to ERα deficiency because these effects are
absent in βERKO mice [65,66].
Alteration of the endocrine profile is a consistent finding
in transgenic mice with targeted deletion of aromatase
gene or ERs (Table 2). For example, serum LH levels were
elevated in adult ARKO mice [6] while serum testosterone
concentrations, though were increased at 12–14 wk of
age, were comparable in wild-type and mutant mice [7].
Similarly, the concentrations of serum testosterone, LH,
and FSH were increased in αERKO males compared to
their wild-type littermates [5,67]. The changes in serum
gonadotropin levels presumably result from alleviation of
estrogen feedback regulation on the hypothalamus-pitui-
tary axis. The regulation of testicular steroidogenesis
appears to be mediated primarily by ERα because changes
in serum steroid hormone levels seen in the αERKO are
absent in βERKO mice. Moreover, administration of a
synthetic estrogen, estradiol benzoate, reduced serum LH
and testosterone levels in wild-type but not αERKO mice
(Fig. 2A), and treatment with the pure antiestrogen ICI
182,780 decreased androgen biosynthesis in wild-type
but not αERKO Leydig cells [67]. The differences in andro-
gen biosynthesis between αERKO and wild-type Leydig
cells were associated with changes in steroidogenic
enzyme activity because ERα deficiency enhanced gene
expression for cytochrome P450 hydroxylase/17α lyase
and 17β-hydroxysteroid dehydrogenase type III; these
enzymes take part in reactions involved in the conversion
of the steroid substrate cholesterol to testosterone (Fig.
2B). Consistent with these observations, a recent report
showed that DES decreased testosterone production of
wild-type fetal and neonatal testes but not ERα-/- [68].
III. Studies of xenoestrogens
Although there had been long standing evidence that
male reproductive tract development is subject to estrogen
action [39,69], scientific attention to the role of estrogen
in reproductive activity was highlighted only recently by
public concerns that exposures to environmental chemi-
cals may adversely affect the endocrine and reproductive
systems. Exposures of laboratory animals and wildlife to
high levels of estrogenic chemicals resulted in a number of
abnormalities, including reduced gonad size, feminiza-
tion of genetic males, and low sperm count and quality. In
this regard, estrogenic activity has been attributed to a
diverse array of steroidal and non steroidal compounds,
including industrial chemicals (e.g., polychlorobiphenyls,
alkyphenols, pesticides (e.g., DDT derivatives, methoxy-
chlor, kepone), pharmaceutical agents (e.g., DES,
tamoxifen, raloxifene), phthalates (e.g., di-2-ethylhexyl-
phthalate, di-n-butyl phthalate), and phytoestrogens (e.g.,
genistein, daidzen) [1,70,71]. While there is no clear data
demonstrating that environmental chemicals are the
cause of reproductive anomalies in humans, the homol-
ogy in organ systems between animal models and
humans indicates a potential for adverse effects on sexual
development and function.
Although binding affinity of xenoestrogens for ERs is low,
ranging from 0.0001% to 1% of E2 levels, these chemicals
have the ability to activate ERα and ERβ as agonists or pre-
vent their binding by endogenous ligands when acting as
antagonists [72,73]. Just as diverse as the number of
chemicals known to exhibit estrogenic activity, the profile
of biological responses to exogenous chemicals is affected
by a variety of factors in reproductive tissues: animal
strain and species differences, relative amounts of ER sub-
types, presence of EREs, recruitment of co-regulatory pro-
teins (co-activators and repressors), binding to plasma
proteins, chirality of chemicals, and multiple mechanisms
of action (e.g., estrogenicity versus antiandrogenicity)
[71,74]. Specifically, xenoestrogens evoke estrogenic
responses and cause their effects by mimicking and/or
blocking the actions of endogenous E2 (agonist versus
antagonist), and these effects may be result in changes in
steroid hormone receptor gene expression, altered steroid
Table 2: Endocrine profiles of mice deficient in estrogen biosynthesis or estrogen receptor protein
FSH LH Testosterone 17β-estradiol References
ARKOa Elevated Elevated Elevated Absent 6,7
αERKOb ND Elevated Elevated ND 5,67
βERKOc Normal Normal Normal ND 66
αβERKOd ND Elevated Elevated ND 64
ND, Not determined.Reproductive Biology and Endocrinology 2005, 3:51 http://www.rbej.com/content/3/1/51
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hormone metabolism, cross-talk between ERs and other
signaling systems (e.g., aryl hydrocarbon and EGF), and
interference with serum protein binding [75-77]. It has
also been suggested that the presence of xenoestrogens in
the hormonal milieu of estrogen-sensitive tissues has the
effect of potentiating E2 action [78]. The nature of the ERE
in the promoter region of target genes may affect cellular
response as indicated by the ability of ERβ to activate EREs
from the vitellogene while ERα showed greater activation
at the more divergent LH EREs in COS-1 cells [79].
Because ERs function as dimers, estrogen responsive genes
may respond differently to ERα and ERβ homodimers or
ERα/ERβ heterodimers following ER activation [80]. Fur-
thermore, there are ligand-dependent differences in the
ability of ERα and ERβ to bind co-regulatory proteins
[21,81]. Thus, the cellular response to ER agonists and
antagonists is the result of interaction between several
factors.
Estrogen regulates testicular steroidogenesis, acting via ERα because administration of an estrogenic chemical, estradiol ben- zoate, suppressed pituitary LH secretion and serum testosterone levels in wild-type but not αERKO mice (ref. 67)(A) Figure 2
Estrogen regulates testicular steroidogenesis, acting via ERα because administration of an estrogenic chemical, estradiol ben-
zoate, suppressed pituitary LH secretion and serum testosterone levels in wild-type but not αERKO mice (ref. 67)(A). ERα 
deficiency enhanced gene expression for cytochrome P450 hydroxylase/17α lyase and 17β-hydroxysteroid dehydrogenase type 
III in αERKO Leydig cells compared to wildtype (WT) (B), indicating that ERα regulates androgen biosynthesis by mediating 
changes in steroidogenic enzyme activity (ref. 67). Copyright 2003, The Endocrine Society.Reproductive Biology and Endocrinology 2005, 3:51 http://www.rbej.com/content/3/1/51
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ER agonists regulate androgen biosynthesis in Leydig cells Figure 3
ER agonists regulate androgen biosynthesis in Leydig cells. Incubation of mature rat Leydig cells, from 90-day old rats, with 
estrogenic chemicals, i.e., bisphenol A (BPA)(A), the synthetic estrogen diethylstilbestrol DES (B) and a biologically active 
metabolite of the pesticide methoxychlor (HPTE)(C), caused an inhibitory effect on androgen biosynthesis albeit at different 
doses. Using RT-PCR, ERβ was not detected in these cells, implying that inhibitory effects were ERα-mediated (ref. 89). Copy-
right 2004, The Endocrine Society.Reproductive Biology and Endocrinology 2005, 3:51 http://www.rbej.com/content/3/1/51
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Endocrine regulation of the testis Figure 4
Endocrine regulation of the testis. Pituitary gonadotropins are the chief regulators of testicular function; FSH acts through its 
receptors in Sertoli cells (FSHR) to regulate spermatogenesis and LH stimulates androgen production by Leydig cells after 
binding to LHR. However, gonadal steroids, i.e., androgen and estrogen, and other agents that bind or prevent binding to ster-
oid hormone receptors (androgen receptor AR, ERα, and ERβ), which are present in Sertoli cells, germ cells and Leydig cells 
also regulate testicular function. The pathway mediated by adenosine-3',5'-cyclic monophosphate (cAMP) appears to be the pri-
mary intracellular signaling pathway in all testicular cells. However, several growth factors e.g., insulin like growth factor-1 
(IGF-1) and epidermal growth factor (EGF), acting via their receptors, IGF-1R and EGF-R, possibly modulate AR and ER-medi-
ated pathways. Thus, testicular function is regulated by interactions between several signaling pathways, some acting locally, 
e.g., AR and ER-mediated pathways, and others indirectly by modulating hypothalamus-pituitary function. Hormonal activation 
of transcriptional gene activity results in changes in cell differentiation and function. PMC, peritubular myoid cell; CRE, cAMP-
responsive elements, ARE, androgen-responsive elements; ERE, estrogen-responsive elements.Reproductive Biology and Endocrinology 2005, 3:51 http://www.rbej.com/content/3/1/51
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A detailed discussion of the effects of environmental
chemicals on male reproduction is outside the scope of
the present review and can be found elsewhere [82,83].
However, studies of estrogenic chemicals have been con-
ducted in laboratory species with low (physiological) and
high (pharmacological) doses. Data from these investiga-
tions indicate that estrogen action is dose-dependent and
may be stimulatory or inhibitory. For example, exposure
to E2 restored spermatogenesis to the germ cell-depleted
testis of hypogonadal mice [84], decreased the rate of
apoptosis and stimulated proliferation of mouse and rat
spermatogonia in vitro [43,85], and induced renewal of
spermatogonial stem cells in the testis of the Japanese eel
[86]. On the other hand, incubation with E2 and DES was
found to inhibit development of spermatogonia, Leydig
cells and Sertoli cells in the fetal rat testis [87]. Adminis-
tration of low doses of the industrial and estrogenic chem-
ical bisphenol A (BPA) reduced spermatogenesis in mice
[88], decreased DNA synthesis by immature rat Leydig
cells (author's unpublished observations), and sup-
pressed androgen biosynthesis by mature rat Leydig cells
(Fig. 3). The effects of E2 and BPA on spermatogonial divi-
sions and Leydig cell steroidogenesis were blocked by co-
incubation with antiestrogens ICI 164384 and ICI
182,780, respectively, indicating that these effects were
ER-mediated [1,89]. There is also evidence showing that
E2 regulates ER gene expression in a dose-dependent
manner because chronic exposures of mice to 0.5 or 50
µg/ml BPA decreased ERβ and increased ERα gene expres-
sion in germ cells [90] but a single injection of estradiol
benzoate at high doses (500 µg) caused the opposite effect
in prepubertal rats, i.e., decreased ERα mRNA levels and
increased ERβ expression [91]. Disparities in data from
different laboratories are probably due to several factors,
which act to moderate estrogen signaling in sensitive tis-
sues, e.g., interaction between transcriptional and non-
transcriptional signaling pathways, receptor cross-talks,
unpredictable mixture effects, and changes in steroid pro-
duction and action. In addition, an inverted U-shaped
dose-response, in which low doses are stimulatory and
high doses are inhibitory, has been proposed for estrogen
action in reproductive tissues [92].
In agreement with studies conducted in rodents, evidence
supporting a direct role for estrogen in male reproductive
tract development was collected from men. For example,
poor semen quality has been a consistent finding in male
patients with mutations in ERα [52] as well as those suf-
fering from aromatase deficiency [53,54]. A recent study
involving a large cohort of men concluded that prenatal
DES exposure is associated with testicular cancer and mal-
formations of the genitalia although fertility was not
affected [93]. Increased incidence in testicular cancer was
thought to be due to early life-stage exposures to environ-
mental estrogens and/or antiandrogens, which interfere
with the ability of gonadal steroids to support tissue dif-
ferentiation in the fetal period [94,95]. Indeed, elevated
blood estrogen levels in dizygotic twin pregnancies are
known to increase the risk of testicular cancer in males
[96]. Growing epidemiological evidence in support of
these observations has led to the hypothesis, which states
that a testicular dysgenesis syndrome (TDS) that is charac-
terized by hypospadias, testicular cancer, abnormal sper-
matogenesis and undescended testis, is the result of
interaction between genetic and environmental factors,
including inappropriate exposures to endocrine-active
chemicals [97,98]. The growing incidence of TDS in the
population implies that changes in steroid hormone syn-
thesis and action cause greater effects during sexual differ-
entiation in humans, as in rodents, but it is not clear that
sperm function and fertility are affected in adulthood.
A series of data were published lately to highlight aspects
of estrogen action in the testis. First, it was observed that
neonatal treatment of prepubertal rats with DES alone
(0.1 µg) induced only minor effects, which were amplified
after suppression of androgen production and action.
Thus, it was hypothesized that reduced androgen levels
render the reproductive tract more sensitive to estrogen
stimulation, and that the ratio between androgen and
estrogen, rather than their absolute levels, is the critical
determinant of E2 action [99,100]. Curiously, this line of
thinking does not explain similarities in the phenotypes
of ARKO and αERKO mice, which have comparable
serum androgen levels but exhibit different E2 levels
(Table 2). However, there are suggestions that phenotypic
similarities in ARKO and αERKO mice are possibly due to
the confounding effects of growth factors that activate sig-
naling pathways mediating E2 activity, e.g., EGF [59]. Also
of interest are recent data showing that the presence of soy
in the diet decreases body and testis weights, suppresses
gonadotropin secretion, and retards germ cell develop-
ment in the rat [101]. These findings have implications for
analysis of estrogen action in the testis because: 1) The
normal rat chow contains significant levels of phytoestro-
gens (200–300 mg/kg), potentially interfering with the
action of E2 and estrogenic chemicals in reproductive tis-
sues [102,103]; and, 2) Putative health benefits associated
with soy-based diets may be confounded by phytoestro-
gen signaling in the testis [104]. Although there is no evi-
dence that consumption of soy-based diets has
deleterious effects on testicular function, the possibility
that such effects may occur in the prepubertal period, i.e.,
in infanthood, cannot be discounted as this population is
not routinely examined for reproductive health. Because
acquisition of adult sexual behavior is dependent on
priming of sexually dimorphic hypothalamic nuclei by
steroid hormones in the perinatal period [105], such eval-
uations seem to be warranted.Reproductive Biology and Endocrinology 2005, 3:51 http://www.rbej.com/content/3/1/51
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IV. Conclusion
The major source of E2 biosynthesis is the testis in rodents
and adipose tissue in men but the receptor protein (ERα
and ERβ) is localized to most cell types in the testis of
both species in consonance with a physiological role for
estrogen in testicular development and function (Fig. 4).
It is therefore not surprising that targeted deletion of the
aromatase gene, ERα, and/or ERβ caused a variety of tes-
ticular anomalies in mutant mice. For example, evidence
for direct ER-mediated action in testicular cells is provided
by disruption of spermatogenesis in ARKO and αERKO
mice and the requirement for ERα for estrogen action in
Leydig cells [6,7]. Moreover, elevated serum LH levels in
αERKO mice indicate that ERα deficiency jeopardizes ster-
oid hormone negative feedback mechanisms in the
hypothalamus-pituitary axis [5,106]. These observations
have clinical relevance because men with disorders of glu-
cose metabolism and those with increased body mass
index (i.e., overweight or obese) exhibit elevated serum
E2 levels [107] with the potential for enhanced estrogen
action in the testis. However, a number of confounding
variables need resolution in order to clearly identify the
mechanisms associated with the physiological actions of
E2 in the testis. In this regard, new experimental
approaches are needed, and may include: i) use of tissue-
specific knockouts in order to remove effects of concur-
rent ER-mediated activity in the hypothalamus and/or
pituitary [108]; ii) analysis of signaling pathways not
mediated by ligand binding of ERα and/or ERβ [109,110];
iii) investigation of the role of membrane ER signaling in
the regulation of testicular function [111,112]; iv) assess-
ment of the influence of genetic background on estrogen
action [96,113]; v) development of methods for measur-
ing bioavailability of estrogens in the body in order to
define dose-effect relationships [114,115]; and vi) use of
techniques that maintain the normal hormonal milieu of
reproductive tract tissues during investigation, i.e., as
related to gonadotropin and androgen action [116]. A
combination of these approaches will advance our under-
standing of the regulatory role of E2 in the mammalian
testes.
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